What’s Going On With RAPT Therapeutics Stock On Wednesday?
Tuesday, the FDA verbally notified RAPT Therapeutics Inc (NASDAQ:RAPT) that a clinical hold has been placed on the company’s Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase 2a trial in asthma.
The shares closed at $6.87 on Tuesday, sharply down from $25.97 at Friday’s close.
Wednesday, RAPT Therapeutics shares are trading higher on a rebound amid increased volatility in the stock, which sold off yesterday after the clinical trial setback.
RAPT shares are trading on a strong session volume of 11.01 million, compared to an average volume of 628.843K, as per data from Benzinga Pro.
However, certain analysts downgraded RAPT Therapeutics after the trial setback:
HC Wainwright downgraded RAPT Therapeutics from Buy to Neutral, noting that the FDA clinical …
Full story available on Benzinga.com
